Viral Dynamics of Acute HIV-1 Infection

Viral dynamics were intensively investigated in eight patients with acute HIV infection to define the earliest rates of change in plasma HIV RNA before and after the start of antiretroviral therapy. We report the first estimates of the basic reproductive number (R 0), the number of cells infected by the progeny of an infected cell during its lifetime when target cells are not depleted. The mean initial viral doubling time was 10 h, and the peak of viremia occurred 21 d after reported HIV exposure. The spontaneous rate of decline (α) was highly variable among individuals. The phase 1 viral decay rate (δI = 0.3/day) in subjects initiating potent antiretroviral therapy during acute HIV infection was similar to estimates from treated subjects with chronic HIV infection. The doubling time in two subjects who discontinued antiretroviral therapy was almost five times slower than during acute infection. The mean basic reproductive number (R 0) of 19.3 during the logarithmic growth phase of primary HIV infection suggested that a vaccine or postexposure prophylaxis of at least 95% efficacy would be needed to extinguish productive viral infection in the absence of drug resistance or viral latency. These measurements provide a basis for comparison of vaccine and other strategies and support the validity of the simian immunodeficiency virus macaque model of acute HIV infection.

[1]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[2]  J. Gerberding,et al.  The Care of Persons with Recent Sexual Exposure to HIV , 1998, Annals of Internal Medicine.

[3]  D. Cooper,et al.  Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. , 1997, The Journal of infectious diseases.

[4]  L M Wahl,et al.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection , 1997, Journal of virology.

[5]  J. Gold,et al.  ACUTE AIDS RETROVIRUS INFECTION Definition of a Clinical Illness Associated with Seroconversion , 1985, The Lancet.

[6]  A S Perelson,et al.  Rate of HIV‐1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen , 1998, AIDS.

[7]  P. Kahn Susceptibility Genes: Pointing a Way to Prevention? , 1996, Science.

[8]  D. Cardo,et al.  Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994. , 1995, MMWR. Morbidity and mortality weekly report.

[9]  D. Richman,et al.  Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. , 1997, The Journal of clinical investigation.

[10]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[12]  S. J. Clark,et al.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. , 1991, The New England journal of medicine.

[13]  T. Elbeik,et al.  Activation of virus replication after vaccination of HIV-1-infected individuals , 1995, The Journal of experimental medicine.

[14]  D. Ho,et al.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[15]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[16]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[17]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[18]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[19]  D. Richman,et al.  Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells , 1990, Journal of virology.

[20]  Andrew N. Phillips,et al.  Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response , 1996, Science.

[21]  F. McCutchan,et al.  Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. , 1993, The New England journal of medicine.

[22]  M. Stevenson,et al.  HIV‐1 replication is controlled at the level of T cell activation and proviral integration. , 1990, The EMBO journal.

[23]  J. Justement,et al.  Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Macdonald,et al.  The analysis of equilibrium in malaria. , 1952, Tropical diseases bulletin.

[25]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[26]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[27]  D. Baltimore,et al.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression , 1989, Journal of virology.

[28]  M. Hirsch,et al.  Primary human T-lymphotropic virus type III infection. , 1985, Annals of internal medicine.

[29]  P D Griffiths,et al.  Population dynamics of HIV within an individual after treatment with zidovudine , 1991, AIDS.

[30]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[31]  V. Calvez,et al.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.

[32]  J. Kaldor,et al.  Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. , 1996, The Journal of infectious diseases.

[33]  D. Richman,et al.  Cell-associated viral RNA expression during acute infection with HIV type 1. , 1998, AIDS research and human retroviruses.

[34]  J. Mcdougal,et al.  Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. , 1985, Journal of immunology.

[35]  J. Goedert,et al.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.

[36]  A. Panlilio,et al.  Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. Vol. 47/No. RR-7. , 1998 .